Login to Your Account

China's Cstone raises $260M series B round for I-O pipeline

By Shannon Ellis
Staff Writer

Wednesday, May 16, 2018

SHANGHAI – Suzhou-based Cstone Pharmaceuticals Co. Ltd. continues to wow observers, having obtained the largest series B financing for a Chinese biotech to date, raising $260 million in venture capital financing. That follows a record-breaking series A in July 2016 for $150 million.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription